Ann: Appendix 4C - quarterly , page-8

  1. 9,630 Posts.
    lightbulb Created with Sketch. 349
    CAND,that's a valid question,and not downramping at all.I know you've asked VON,but I'll give you my take on it.I havent held that long,but if you've held for 2.5 years,and expecting a product to start sales,and it didnt eventuate,I would have sold to.
    In my discussions with the company,the pericoach has taken the front seat,as it can get to market first,and therefore bring in money quicker.It may appear the Burette has been swept under the carpet,however I think there has been some red tape issues in some countries with it,but I'm led to believe it's still a goer.In one of the presentations it says there doing some trials in some Australian Hospitals,and outcomes pending.I totally understand some past holders frustrations,but that's the market for you.I guess the company has to push the product,that will make money first,and at this stage it's the pericoach
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.